Get the Stockscreener App
25.27
0.32%
-0.08
After Hours:
25.55
0.28
+1.11%
Castle Biosciences Inc stock is traded at $25.27, with a volume of 270.32K.
It is down -0.32% in the last 24 hours and down -18.03% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
See More
Previous Close:
$25.35
Open:
$25.81
24h Volume:
270.32K
Relative Volume:
0.71
Market Cap:
$751.31M
Revenue:
$344.23M
Net Income/Loss:
$-24.16M
P/E Ratio:
-29.83
EPS:
-0.8471
Net Cash Flow:
$28.33M
1W Performance:
-1.35%
1M Performance:
-18.03%
6M Performance:
+11.13%
1Y Performance:
+21.26%
1-Day Range:
$25.08
$26.19
1-Week Range:
$24.74
$26.19
52-Week Range:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
25.27 | 753.69M | 344.23M | -24.16M | 28.33M | -0.8471 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Hedge Fund Moves: Can Castle Biosciences Inc deliver alpha2026 Top Decliners & High Return Trade Opportunity Guides - baoquankhu1.vn
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk - Yahoo Finance
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE StudySlideshow (NASDAQ:CSTL) 2026-03-23 - Seeking Alpha
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Valuation Update: Whats next for Castle Biosciences Inc stock2026 Retail & Weekly Hot Stock Watchlists - baoquankhu1.vn
Breakout Watch: Can Castle Biosciences Inc maintain its current growth rateMarket Performance Report & Safe Entry Point Identification - baoquankhu1.vn
What are the future prospects of Castle Biosciences IncWeekly Stock Report & Risk Controlled Daily Plans - baoquankhu1.vn
Maetzold, Castle Biosciences CEO, sells $500k in CSTL stock By Investing.com - Investing.com India
Maetzold, Castle Biosciences CEO, sells $500k in CSTL stock - Investing.com
Derek Maetzold Sells 650 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 18,650 Shares of Stock - MarketBeat
Castle Biosciences (CSTL) CEO sells 19,300 shares under 10b5-1 plan - Stock Titan
Castle Biosciences introduces 487-gene panel to guide JAK inhibitor or Th2 therapy decisions - Traders Union
Castle Biosciences (CSTL) loses 16.8% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Risk Recap: What’s Castle Biosciences Inc.’s historical returnGold Moves & Growth Focused Entry Point Reports - baoquankhu1.vn
Castle Biosciences (NASDAQ: CSTL) CEO sells 30,779 shares under 10b5-1 plan - Stock Titan
Big Picture: What is the implied volatility of Castle Biosciences IncQuarterly Trade Report & Long-Term Safe Return Strategies - baoquankhu1.vn
Castle Biosciences (NASDAQ:CSTL) Insider Sells $526,582.12 in Stock - MarketBeat
Castle Biosciences Officer Sells Shares - TradingView
Castle Biosciences (NASDAQ: CSTL) CCO sells 20,863 pre-planned shares - Stock Titan
Castle Biosciences (CSTL) Study Validates DecisionDx-Melanoma Te - GuruFocus
Castle Biosciences (CSTL) CEO sells 44,125 shares under 10b5-1 plan - Stock Titan
Prospective, Multi-center Study Published in Future - GlobeNewswire
New melanoma test flags patients who can skip lymph node biopsy - Stock Titan
CSTL (NASDAQ: CSTL) Form 144 shows proposed resale of 20,863 shares - Stock Titan
Derek Maetzold sells shares; CSTL (NASDAQ: CSTL) Form 144 lists large late‑2025 trades - Stock Titan
New study confirms sentinel lymph node prediction accuracy, Castle Biosciences asserts - Traders Union
Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k - Investing.com Nigeria
Castle Biosciences Inc (CSTL) CFO Frank Stokes Sells 6,001 Shares - GuruFocus
Insider Selling: Castle Biosciences (NASDAQ:CSTL) CFO Sells 6,001 Shares of Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Director Sells 7,403 Shares of Stock - MarketBeat
Castle Biosciences (CSTL) CFO sells 6,001 shares under 10b5-1 plan - Stock Titan
Castle Biosciences (CSTL) director exercises options and sells shares - Stock Titan
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest - GlobeNewswire
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2025 earnings call transcript - MSN
Aug Wrap: Whats next for Castle Biosciences Inc stockVolume Spike & Expert Verified Movement Alerts - baoquankhu1.vn
Death Cross: Will Castle Biosciences Inc benefit from current market trendsEarnings Growth Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Castle Biosciences, Inc. (CSTL) reports Q4 loss, beats revenue estimates - MSN
Castle Biosciences, Inc. (CSTL) expected to beat earnings estimates: What to know ahead of Q4 release - MSN
How Castle Biosciences (CSTL) Story Is Shifting With New Revenue Targets And Fair Value - Yahoo Finance
Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k By Investing.com - Investing.com UK
Frank Stokes Sells 7,000 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Castle Biosciences (CSTL) CCO logs RSU grant, conversions and tax share withholdings - Stock Titan
Castle Biosciences (CSTL) CEO details RSU grants, conversions and tax share disposals - Stock Titan
Castle Biosciences: Interview With Founder, CEO, And President Derek Maetzold About The Molecular Diagnostics Company - Pulse 2.0
Castle Biosciences Stock Hits Day Low of $27.22 Amid Price Pressure - Markets Mojo
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB - The Manila Times
Melanoma test may let some patients skip lymph node surgery - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Lowered to Hold Rating by Zacks Research - MarketBeat
Castle Biosciences to Present Data at SSO 2026 on DecisionDx-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB - Bitget
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas - Bitget
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):